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A B S T R A C T
Ovarian clear cell carcinomas (OCCC) are rare aggressive, chemo-resistant tumours comprising approximately
13% of all epithelial ovarian cancers, which have distinct clinical and molecular features, when compared to
other gynaecological malignancies. At present, there are no specific licensed targeted therapies for OCCC, al-
though a number of candidate targets have been identified. This review focuses on recent knowledge under-
pinning our understanding of the pathogenesis of OCCC including direct and synthetic-lethal therapeutic stra-
tegies in particular focussing on ARID1A deficiency. We also discuss current targeted clinical trials and
immunotherapeutic approaches.
1. Introduction
Epithelial ovarian carcinoma is the commonest cause of gynaeco-
logical cancer-associated death [1]. Worldwide, there were 239,000
new cases diagnosed in 2012 alongside 152,000 deaths [2]. Survival
figures have not significantly changed since the 1980′s, (European 5-
year survival remains around 40% [3]), mainly due to the insidious
onset of most cases, which are usually at advanced stages at presenta-
tion. Part of the lack of improvement is thought to be due to the fact
that ovarian cancer subtypes are treated as a single disease, even in
large-scale clinical trials, despite the existence of different histological
subtypes and molecular drivers. Ovarian clear cell carcinoma (OCCC)
was formally described in the World Health Classification in 1973 as
“tumours composed of clear cells containing glycogen and resembling
those of the renal cell carcinoma and/or with the presence of hobnail
cells” [4]. They are traditionally considered high-grade carcinomas [5].
A SEER registry analysis of 28,082 women with epithelial ovarian
cancer identified 5% had clear cell, 13% endometrioid with 49% having
papillary serous cancer [6]. Women with a clear cell diagnosis were
younger, with a median age of 55 years compared to 64 years in serous
carcinoma and were associated with a significantly worse five-year
survival, (p < 0.001) compared to endometrioid, serous and mucinous
histological subtypes, across all stages [6]. OCCC has a variable
worldwide distribution with the highest prevalence in Japan (25%) [6],
although the reasons for this are unknown, but perhaps are related to
the elevated incidence of endometriosis. The majority of OCCC patients
are diagnosed at an early stage, with studies showing between 49–81%
of patients are diagnosed at stage I and II [6,7], often presenting with
large unilocular cysts [8]. A retrospective Japanese OCCC study as-
sessed 254 OCCC’s and found that stage I and II overall survival was
88% and 70% respectively, with stage III and IV being 33% and 0%
respectively, highlighting that outcomes in advanced stages of OCCC
are particularly poor [9].
The main risk factors for OCCC include nulliparity, endometriosis
and tubal ligation [10]. Endometriosis has been associated with
33%–37% of OCCC’s [10], and the presence of endometriosis has a
relative risk of 3.37 (1.24–9.14) for OCCC [11,10]. Endometriotic cysts
(the precursors for OCCC and endometroid carcinomas) contain free
iron, which have been shown to lead to increased oxidative stress and
frequent DNA mutations. Gene expression analysis of cell lines that had
exposure to cyst contents showed similar patterns of gene expression to
OCCC, suggesting there may be a correlation with the endometriotic
environment [12]. As such this accumulation during a woman’s re-
productive period may thus be a possible cause for the malignant
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chances in the cysts. Unlike high grade serous ovarian cancers (HGSOC)
or endometrioid cancers however, OCCC’s show no family history [13]
and as such BRCA1 and BRCA2 germline mutations are rare [14].
Immunohistochemically, OCCCs are CK7+/CK20- [15], tend to be
negative for hormone receptors ER (oestrogen receptor) and PR (pro-
gesterone receptor), Wilms Tumour 1 (WT1) and p53 [16]. Hepatocyte
nuclear factor 1-β (HNF1-β) is over-expressed in OCCC and useful in
cases of diagnostic uncertainty (82.5% sensitivity and 95.2% specificity
for OCCC vs. HGSOC) [17]. An IHC research tool has been devised to
predict ovarian histological subtypes and includes WT1, p16, DKK1,
vimentin, p53, PR, TFF3, HNF1B and MDM2 and ARID1A and gives a
probability based on the expression statuses [18]. In 2010, Kurman and
Shih proposed a classification system of ovarian cancers into two types
based on molecular features [19]. Type I tumours are low-grade and
underpinned by KRAS, BRAF and PTEN mutations with microsatellite
instability. Type II tumours, such as high grade serous, are genetically
unstable with mutations in TP53, BRCA1 and BRCA2 and are aggressive
in nature. OCCC and endometrioid carcinomas are considered as Type 1
endometriosis related tumours with similar molecular features and are
considered genetically stable (other subsets being LGSOC and germ cell
or transitional cell-related (Mucinous and Brenner tumours) [20].
The standard of care treatments for OCCC patients involves major
debulking surgery followed by six cycles of 3 weekly post-operative
chemotherapy of paclitaxel combined with carboplatin, as per all epi-
thelial ovarian cancers [21]. In advanced cases, no residual disease
after chemotherapy is associated with improved overall survival (OS)
[9], however overall the response rates to chemotherapy are lower in
OCCC than in, for example, serous ovarian cancers; with overall sur-
vival times of 21.3 months compared to 40.8 months for HGSOC and
progression free survival times of 9.6 months in OCCC compared to
16.1 months in serous ovarian carcinomas [22]. A retrospective cohort
study of OCCC patients showed that 50% with stage III/IV disease had
chemotherapy refractory or resistant disease compared to 9.7% of
women with early stage disease [23]. Chemotherapy response rates in
the recurrent setting range between 1–9% [24,25]. These studies
highlight that other therapeutic strategies involving novel targeted
agents would offer improvements over current chemotherapeutic regi-
mens.
The advent of the availability of targeted therapies, widespread
genetic testing, increase in clinical trials and international collaboration
and working groups have significantly altered the treatment landscape
for patients with ovarian cancer. However, this focus has mainly been
on HGSOC and no specific OCCC therapies have been licensed to date.
There have been limited targeted therapeutic studies specifically
focussing on OCCC, in part due to the rarity of the disease and the fact
that OCCC have a low frequency of BRCA1/2 mutations, and although
new agents such as Poly (ADP-ribose) Polymerase (PARP) inhibitors are
approved for HGSOC, current clinical evidence for efficacy in OCCC is
lacking. Increasingly, a greater understanding of the molecular patho-
genesis and heterogeneity of cancer has led to the development of more
effective treatment strategies in various tumour types. In this article,
the recent advances in our understanding of the molecular character-
istics and pathogenesis of OCCCs and how they may facilitate the de-
velopment of targeted therapeutic strategies are reviewed.
2. Actionable alterations in OCCC
Molecular profiling of ovarian cancers has highlighted that the
different histological subtypes of ovarian cancer are underpinned by
distinct molecular profiles. In particular, non-epithelial histological
ovarian cancers are underpinned by pathognomonic driver mutations
i.e. DICER1 mutations in Sertoli-Leydig tumours, FOXL2 mutations in
Granulosa cell tumours of the ovary and SMARCA4 mutations in Small
Cell tumours of the Ovary [105–110]. These studies have also shown
that epithelial ovarian cancers are underpinned by different repertoires
of mutations. For instance, HGSOC invariably harbours TP53 mutations
and immunohistochemistry of p53 is now used clinically to aid diag-
nosis [110]. Moreover, these HGSOC’s harbour DNA repair related
defects including BRCA1 and BRCA2 germline and somatic mutations.
Low grade and mucinous serous ovarian cancers tend to harbour more
frequent mutations in BRAF and KRAS and exhibit ERBB2 amplifica-
tions. Ovarian clear cell and endometrioid tumours, whilst histologi-
cally distinct, harbour a similar mutational profile, with high fre-
quencies of ARID1A mutations (around 40–57% in OCCC and 30% in
endometrioid ovarian tumours) [41,42] (Table 1).
Although the number of OCCC specific trials are low, a recent report
of a 115 patient series in which some had received targeted therapies
such as bevacizumab, nintedanib, PARP inhibitors or PI3K/MTOR in-
hibitors in the second line resulted in an objective response rate (ORR)
of 30% for the whole cohort, suggesting that access to experimental
therapy could improve response rates in recurrent disease [26]. The
majority of recent efforts to target recurrent genetic alterations in OCCC
have focussed on targeting ARID1A deficiencies, given the high fre-
quency of mutations in the disease, however other studies have fo-
cussed on targeting angiogenesis and more recently the use of im-
munotherapeutic agents, (Table 2 and 3).
3. Targeting angiogenesis in OCCC
Anti-angiogenic agents inhibit the formation of blood vessels (an-
giogenesis) through inhibition of pro-angiogenic factors such as vas-
cular endothelial growth factor (VEGF), basic fibroblast growth factor
(bFGF) and platelet-derived growth factor (PDGF) [27,28]. Gene ex-
pression profiling studies have highlighted the similarities between
OCCC and with clear cell carcinoma (RCCC) of the kidney, where anti-
angiogenic treatments are licensed for clinical use. In particular OCCC’s
show upregulation of the IL6-STAT3-HIF signalling pathway, which is
involved in angiogenesis, in up to 49% of cases and as such, OCCC may
Table 1
Published frequency of common ovarian clear cell cancer (OCCC) mutations.








Summary of published targets and pathways in OCCC.
Pathway Target Drug Reference
ARID1A Synthetic
lethality
ATR AZD6738, VX-970 [69]
BCR/ABL/SRC dasatinib [71]
ROS induction elesclomol [102]
BET (BRD2) JQ1 [66]
EZH2 GSK126 [60]





PARP talazoparib, olaparib [68,104]
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preferentially benefit from targeted anti-angiogenic therapy [29,30]. A
number of studies have therefore tried anti-angiogenics in OCCC,
however the majority of these have showed limited efficacy. The GOG-
254 study investigating sunitinib (a VEGFR and PDGFR inhibitor) de-
monstrated limited activity with an ORR of 6.7% in a phase II trial of 35
patients with recurrent OCCC setting, with a median PFS of 2.7 months
and median overall survival of 12.8 months (GOG-254) [31]. The NRG-
GY001 phase II study of single agent Cabozantinib, (a VEGFR, MET and
RET kinase inhibitor) in patients with recurrent OCCC assessed 13 pa-
tients and resulted in a median PFS of 3.6 months and an overall sur-
vival of 8.1 months. Toxicities included a grade 5 thromboembolic
event and no objective tumour responses were seen; although one pa-
tient received Cabozantinib for 23 cycles and remained on treatment at
the point of data cut off [32]. The international phase II trial in-
vestigating ENMD-2076, an oral multi-target kinase inhibitor against
Aurora kinase-A and potent anti-angiogenic activity against VEGFR, in
unselected OCCC, did not meet its pre-set alternative hypothesis of a 6-
month PFS rate of 40% compared to a null hypothesis of 20%, reaching
a PFS rate of 22% at 6 months [33]. Of note however a subgroup
analysis identified that patients with ARID1A protein loss correlated
with a better PFS on ENMD-2076, with ARID1A loss of expression pa-
tients showing a 33% PFS rate compared with a 12% PFS rate in the
ARID1A IHC positive population, p=0.023). The mechanistic basis
behind this finding is however unknown. A number of other trials in
ovarian cancer are investigating angiogenesis (Table 3) including a
randomised Phase II multi-centre international study of nintedanib
(BIBF 1120), versus chemotherapy in recurrent OCCC or the en-
dometrium [34] (Table 3). Nintedanib is a novel, orally available, po-
tent triple angiokinesis inhibitor that mainly blocks VEGFR 1–3, FGFR
1–3 and PDGF receptor α and β. The assessment of plasma levels of
CRP, IL-6, soluble VEGF and soluble VEGFR, and associated correlation
with response, PFS and OS will be studied within the NiCCC (ENGOT-
GYN1) trial [34].
There are perhaps a number of reasons why there has been no real
response seen with these anti-angiogenic drugs to date in OCCC. The
patient characteristics and differences in biology (increased frequency
in ARID1A/ PI3K pathway alterations in OCCC and lack of VHL mu-
tations compared to RCC) may explain the limited efficacy as single
agent treatment. The regimens e.g. sunitinib (4:2) 4 weeks on and 2
weeks off (GOG-254) may not have been optimally tolerated. For ex-
ample in RCC, clinicians initially used this scheduling but can now opt
for a variation in scheduling 2:1, with better tolerance. None of these
trials had pre-selected stratification of anti-angiogenic markers and
their translational work is still awaited. Detailed genomic information
from these patient biopsies is critical to understanding responses and
resistance mechanisms and for the Identification of predictive bio-
markers specifically for nintedanib or for other VEGR pathway in-
hibitors, of which have not yet been established for use in clinical
practice. Soluble VEGFR2 however has been shown to decrease over the
first 4 weeks of nintedanib treatment, highlighting a potentially useful
blood biomarker of response [34].
4. Targeting the copy number landscape of OCCC
On the whole, unlike HGSOC, OCCC are not characterised by high
levels of genomic instability in agreement with the lower frequency of
germline BRCA1/2 mutations seen in these cancers [35]. Copy number
profiling of a series of 50 OCCC’s using microarray comparative
genomic hybridisation, found that OCCC’s could be classified into two
distinct clusters, according to their pattern of copy number alterations,
a surrogate of the degree of genomic instability. These clusters were
identified with different clinical outcomes, with cluster 1 having a
higher prevalence of ‘complex-sawtooth’ (multiple focal gains and
losses) and ‘firestorm’ (i.e. high-level amplification) patterns [36], and
a shorter median progression-free survival compared to cluster 2,
comprising of simple genomic patterns (whole chromosomal arm gains
and losses), (11 vs. 65 months, p= 0.009). Of note, cluster 1 was found
to have recurrent amplifications of the human epidermal growth factor
receptor 2 (ERBB2HER2) [37].
Indeed, amplification of certain genomic loci, make these attractive
as potential therapeutic targets [37]. These include recurrent amplifi-
cations of the 17q12 locus which encompasses HER2 seen in 14% of
OCCC, suggestive that HER2 amplified patients could be treated with
HER2 targeted therapies akin to breast cancer. Previous phase II studies
have examined the effectiveness of trastuzumab monotherapy in re-
current EOC with HER2 overexpression, however an overall response
rate of only 7% was observed [38]. Single agents targeting HER2 are
however often ineffective, whereas further benefit has been seen in
combination therapies (targeting multiple HER receptors) or antibody
drug conjugates, such as trastuzumab emtansine (T-DM1) in breast
cancer [39]. Future studies are however warranted to test the effec-
tiveness of such combinations of anti-HER2 agents in combination with
chemotherapy or other targeted agents in OCCC.
Amplification and overexpression of the anti-apoptotic protein,
PPM1D at 17q23, has also been documented in around 10% of OCCC
[40]. PPM1D is an oncogenic phosphatase which functions by nega-
tively regulating p53, Chk2 and ATM. In cell line models PPM1D has
been shown to be selectively required for the growth of PPM1D am-
plified OCCC cell lines, highlighting its potential as a novel target [40].
However, to date no clinically available inhibitors against PPM1D have
been successfully developed despite considerable effort.
5. Targeting the mutational landscape of OCCC
Genetically, 85% of OCCCs have wild-type TP53 and a lower fre-
quency of BRCA1 and BRCA2 germline mutations [35] compared to
HGSOC, meaning newly approved strategies such as PARP inhibitors in
the context of germline BRCA1/2 mutations may be limited clinically
use for these patients. The most significant finding to come from the
molecular characterisation of OCCC is the identification of ARID1A
truncating mutations in 40–57% of this disease, making it the highest
frequency recurrent alteration in OCCC [41–43].
Although ARID1A mutations are the most frequent molecular al-
teration in OCCC, there are a number of additional recurrent alterations
that also occur in patients (Table 1). These may thus represent excellent
targets for combinatorial therapies for patients, (Table 2) and may
highlight the underlying biology of this disease. PI3-kinase pathway
alterations are known to be common in OCCC, with a number of studies
identifying a mutation rate between 29–40% involving PIK3CA
[41,43,44], often co-occurring with ARID1A loss in up to 71% of cases
and in adjacent endometriosis [45]. This is consistent with an in vivo
genetically engineered mouse model (GEMM) that was developed by
Chandler et al, where both ARID1A and PIK3CA mutations were re-
quired to initiate tumour formation [46]. In addition, PTEN mutations
have been described in 5–13% of OCCC cases [47,48], although at the
protein level, loss of PTEN expression has been seen in up to 37.5% of
cases [49]. KRAS mutations have been reported in 9–20% of OCCC
cases [47,48].
Molecular profiling of one of the largest cohorts to date of 125
OCCC cases using the FoundationOne® panel identified a number of
potentially actionable genomic alterations. Forty five percent of sam-
ples originated from primary sites and 13.6% from regional metastatic
sites (peritoneum, fallopian tube, pelvis or uterus) and 40.8% distant
metastatic sites [50]. The most frequent mutation was PIK3CA (52.8%)
followed by ARID1A (51.2%) with 69% of the samples having an al-
teration in at least one component of the mTOR pathway, (including
PIK3CA, AKT2 (7.2%), PTEN (5.6%), FBXW7 (5.6%), PIK3R1 (4.8%),
STK11 (3.2%),MTOR (1.6%), AKT1 (1.6%), AKT3 (1.6%), TSC2 (1.6%),
TSC1 (0.8%), NF1 (0.8%) and RICTOR (0.8%). In cases with ARID1A
loss 56% had co-occurring PIK3CA mutations. These results highlight
the potential benefit of targeting the mTOR pathway in patients with
OCCC.
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6. Synthetic lethal approaches for targeting ARID1A loss of
function mutations
ARID1A mutations were first identified from the seminal study from
Wiegand et al, who analysed the transcriptome of endometriosis-asso-
ciated ovarian carcinomas using RNA-sequencing and identified
ARID1A mutations in 55 out of 119 OCCCs (46%), 10 out of 33 en-
dometrioid (30%) and none in 76 HGSOC cases [42]. In two cases, the
presence of the mutation and the loss of expression of the encoded
ARID1A protein were found in the tumour, contiguous atypical en-
dometriosis but not in the distal endometriosis lesions, suggesting that
ARID1A mutations may be an early event in endometriosis associated
cancer. The vast majority of ARID1A mutations are inactivating; i.e.
either a frameshift mutation or the introduction of a premature stop
codon, leading to early protein termination and as a result lead to
protein truncations and loss of protein expression. The majority of
ARID1A mutations in OCCC are not associated with tumour loss of
heterozygosity (LOH) suggesting that ARID1A is haploinsufficient [42].
OCCCs that are ARID1A mutant often have co-existing mutations in the
PI3K/AKT signalling pathway by having gain of function mutations in
the PIK3CA oncogene or loss of function mutations in PTEN [45].
The ARID1A gene is located on chromosome 1p35.11 and encodes
for a protein (ARID1A, aka BAF250A) that forms a key DNA binding
subunit in the ATP dependent BAF SWI/SNF chromatin-remodeling
complex [51]. BAF modulates nucleosomes, allowing the winding of
DNA around histone cores providing access to the DNA to enable
transcription, DNA repair and replication [41,52,53]. Loss of function
of ARID1A leads to aberrant cell cycle and loss of proliferation control
[54]. In a study analysing 18 tumour types, nearly 20% of human
cancers have mutations in the genes encoding the SWI/SNF complex
[55] making it the most commonly mutated chromatin remodeling
complex in cancer.
As mutations in ARID1A are loss of function, the rationale to target
ARID1A defective OCCC lies on synthetic-lethal approaches. This is
where a defect in either one of two genes has little deleterious effect on
a cell but a combination of defects in both genes causes cell death [56].
The archetypal example of synthetic lethality is that of BRCA1/2 defi-
cient tumours, which leads to a deficiency in the homologous re-
combination (HR) DNA double-strand break (DSB) repair pathway. By
losing HR, cells are unable to repair the DNA lesions caused by Poly
(ADP-Ribose) Polymerase (PARP) inhibitors [57].
Synthetic lethal approaches have been used to identify genetic and
drug synthetic lethal effects associated with ARID1A defects (Fig. 1).
Project Achilles utilised a broad screening approach to identify essential
genes in a large cohort of cancer cell lines. ARID1B, an ARID1A
homolog whose gene product is mutually exclusive with ARID1A in
SWI/SNF complexes, was identified as the number one gene pre-
ferentially required for the survival of ARID1A-mutant cell lines [58].
ARID1A-deficient cancers were found to retain at least one functional
ARID1B allele [59], and by using shRNA knockdown of ARID1B in
ARID1A-deficient cells, Helming et al. showed that loss of ARID1B de-
stabilised the SWI/SNF complex and impaired the proliferative rate of
ARID1A defective tumour cells. However, to date no therapies have
been developed that target ARID1B.
6.1. Epigenetic targeting of ARID1A deficiency
Using a small molecule screen of epigenetic inhibitors, Bitler et al.
highlighted the potential of targeting the antagonistic activity between
SWI/SNF and the enhancer of zeste homolog 2 (EZH2) methyl-
transferase with the EZH2 small molecule inhibitor GSK126, which
triggers apoptosis in ARID1A mutated cells [60]. EZH2, is the catalytic
subunit of the polycomb repressive complex 2, and silences gene ex-
pression through the trimethylation of histone H3 lysine 27
(H3K27me3) [61]. This synthetic-lethal association, was found to be
mediated via upregulation of PIK3IP1, a direct target of EZH2, and
selectivity was further enhanced upon inhibition of PI3K-AKT signaling
[60]. Interestingly, identification of SWI/SNF catalytic subunit
switching has been shown to drive resistance to EZH2 inhibitors in
ARID1A mutated cells, specifically the switch of the mutually exclusive
catalytic subunits SMARCA4 to SMARCA2. Consequently, this subunit
switching leads to upregulation of the direct SMARCA4 target BCL2
(also an ARID1A target gene), leading to hypersensitisation of EZH2
resistant ARID1A mutant cells to the BCL2 inhibitor (ABT263). Com-
bination treatment with both EZH2 (GSK126) and BCL2 inhibitors
(ABT263) led to significant tumour regression in an in vivo GEMM
model (Arid1afl/fl;(Gt) Rosa26Pik3ca*H1047R) [62].
Further work has indicated that pre-clinically, ARID1A mutant
OCCC are selectively sensitive to HDAC2 inhibition. HDAC2 co-re-
presses EZH2 leading to downregulation of the tumour supressor
PIK3IP1, thus inhibiting proliferation and promoting apoptosis [63]. As
a result, ARID1A defective cells are selectively sensitive to the pan
HDAC inhibitor vorinostat. Subsequent work by Bitler et al. has shown
that ARID1A-mutated ovarian cancer models are selectively dependent
on HDAC6 activity, due to HDAC6 upregulation in ARID1Amutant cells
that mechanistically inactivates the apoptosis-promoting function of
TP53 due to deacetylation of histone lysine 120 [64]. This work showed
that treating ARID1A-mutated tumours with the small molecule HDAC6
inhibitor, ACY1215, had a significant survival benefit in vivo. Inhibi-
tion of HDAC6, with ACY1215 has been shown to synergise with anti-
PD-L1 immune checkpoint blockade in ARID1A inactivated ovarian
cancer.
Fukumoto et al identified that ARID1A directly repressed tran-
scription of CD274, with combination treatment in an OCCC GEMM
model showing reduction in tumour burden and improved survival as a
result of activation and stability of interferon-gamma positive CD8 T
cells [65]. The NRG-GY-014 phase II clinical trial, assessing the EZH2
inhibitor tazemetostat in recurrent endometrioid/clear cell carcinoma
Fig. 1. Summary of synthetic lethal targeting strategies of ARID1A deficiency. Inhibitors are listed and specific target or mechanistic rationale in red.
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of the ovary or peritoneum, and recurrent low grade endometrioid
endometrial adenocarcinoma has recently opened (Table 3) and com-
bination strategies are likely to follow.
Recent high-throughput siRNA screens focussing on the kinome in a
large panel of OCCC tumour cell lines identified the bromodomain
protein BRD2, that functions to bind to acetylated histone tails and
promote gene transcription, as essential for survival of ARID1A mutant
cells [66]. As predicted ARID1A mutant cells showed enhanced sensi-
tivity to the BET domain (bromodomain and extra terminal domain)
inhibitors JQ1 and iBET-762, that work by blocking binding of BRD
proteins to acetylated lysine recognition motifs on acetylated histones
[66]. Interestingly inhibition of BRD2 specifically led to a reduction in
ARID1B and SMARCC2 and SMARCE1 suggesting that BRD inhibition
can interfere with SWI/SNF function by affecting the transcription of
multiple components of this multi-protein complex.
Taken together the studies outlined above suggest that epigenetic
targeting of ARID1A defective OCCC could be of clinical benefit.
Currently EZH2 inhibitors are in clinical trials (Table 3) [67] and HDAC
inhibitors such as vorinostat have been approved for T-cell lymphoma
and in clinical trials in many other tumour types. Equally several BET
inhibitors are currently in phase II trials.
6.2. Targeting DNA damage response pathways in ARID1A defective
tumours
ARID1A is recruited to double strand DNA breaks, (DSBs), via its
interaction with Ataxia telangiectasia and RAD3-related protein (ATR)
[68]. ATR is involved in DNA repair, specifically where the DNA da-
mage caused results in tracts of single stranded DNA, such as occurs at
stalled or collapsed replication forks. In addition to initiating the DNA
repair processes that repair and restart replication forks, ATR also
prevents the firing of latent replication forks (that would otherwise
enhance replication fork stress) and causes cell cycle arrest, thus pre-
venting cells from progressing into mitosis in the presence of damaged
DNA. Shen and collegues identified that ARID1A helps DSB processing
to create replication protein A (RPA)-coated single strand DNA (ssDNA)
and sustains ATR activation in response to DSBs. Therefore, cells that
are ARID1A deficient have impaired DNA damage checkpoint regula-
tion [68]. As a result, this impaired G2/M DNA damage checkpoint
activation and defect in the repair of DSB causes sensitivity to the PARP
inhibitor talozaparib, both in vitro and in vivo [68].
A high throughput RNAi screen in the normal breast epithelial cell
line MCF12A and triple-negative breast cancer cell line HCC1143, de-
monstrated that loss of ARID1A caused sensitivity to ATR inhibitors
[69]. ATR inhibition caused increased anaphase bridges, DNA double
strand breaks and apoptosis in ARID1A–deficient cells [69]. The drug
sensitivity was also validated in in vivo models of ARID1A defective
cancers [69]. Loss of function of ARID1A results in the inability to re-
cruit topoisomerase II (TOP2A) to chromatin [107] and delayed cell
cycle progression [69]. The normal role of TOP2A is in decatenating
complex DNA structures prior to the division of the nuclear material at
mitosis. Targeting ARID1A defective cells with an ATR inhibitor, in the
absence of this normal TOP2A function, caused cells to progress into
mitosis prior to the resolution of DNA damage [69].
Given that ARID1A loss results in TOP2A deficiency and cell cycle
defects also leads to an increased reliance on the ATR checkpoint, by
combining ATR inhibitors together with PARP inhibitors is thought to
increase the number of cells entering mitosis prematurely with defec-
tive DNA, resulting in mitotic catastrophe. This approach may also halt
the onset of therapy resistance. Phase I and early phase II trials have
already been initiated investigating this combination and identification
of a cohort that may do particularly well with the combination is of
great interest. An international academic phase II trial of ATR inhibition
in combination with a PARP inhibitor in ARID1A-stratified gynaecolo-
gical cancers (ENGOT-GYN1/NCRI/ATARI) will test the hypothesis that
ATR inhibition alone will be efficacious in ARID1A mutant tumours.
More recently, combination treatment with low-dose radiation and the
PARP inhibitor olaparib greatly improved anti-tumour efficacy, re-
sulting in long-term remission in mice bearing ARID1A-deficient tu-
mours [70].
Taken together, these studies highlight that perturbations of the
DNA repair balance associated with ARID1A-deficiency can be
exploited to develop highly specific anticancer treatments [70], and
highlight the fact that PARP inhibitors that are already approved for
platinum-sensitive HGSOC, may be able to be repurposed for OCCC,
either as single agent or in combination with other therapies.
6.3. Additional ARID1A synthetic-lethal approaches
Miller et al used a focused high throughput drug screen in 12 OCCC
cell lines looking for ARID1A synthetic lethality, with dasatinib, a
multi-target kinase inhibitor, identified as selective for ARID1A mutant
OCCC cell lines [71]. Both short-term and long-term drug sensitivity
assays and isogenic model cell line work showed significant selectivity
for ARID1A mutant cells. Proteomic assessment using sepharose-linked
dasatinib beads identified YES1, (a target of dasatinib) to be sig-
nificantly enriched in the ARID1A mutant cells. ARID1A mutant models
were found to have a significant increase in G1 arrest compared to wild-
type models and dasatinib sensitivity in ARID1Amutant OCCC cell lines
was found to be p21 and Rb dependent and characterized by an
apoptotic response. On the basis of this data, a phase two trial looking
at dasatinib in recurrent ovarian (including OCCC) and endometrial
clear cell carcinoma characterising retention or loss of ARID1A ex-
pression opened in 2014 with an aim to recruit 35 patients
(NCT02059265, Table 3).
A recent study has highlighted the role of altered cellular metabo-
lism as an effective therapeutic strategy in ARID1A deficient cells. In
particular, ARID1A-mutant OCCC cells were shown to have lower levels
of SLC7A11, one component of cystine/glutamate transporter XCT thus
rendering basal levels of glutathione (GSH) low. The XCT complex
imports cystine into the cell in exchange for glutamate, and the cystine
is reduced to cysteine and used by glutamate cysteine ligase (GCL) to
produce reduced glutathione (GSH). Within the cell there is an intricate
balance between GSH and reactive oxygen species (ROS) levels in order
to maintain cellular homeostasis. Disruption of this balance via reduced
GSH leads to higher ROS levels and further perturbation of this balance
with GSH specific inhibitors such as APR-246 causes cell death, due to
unbearable levels of ROS accumulation [72,73].
7. PPP2R1A mutations in OCCC
Although ARID1A mutations are the most prevalent mutations in
OCCC, there are a number of other mutations that have been identified
as potential drivers, including PPP2R1A seen in 7.1% of OCCC [41].
PPP2R1A codes for Protein phosphatase 2A (protein phosphatase 2,
regulatory subunit A), which is a serine-threonine phosphatase that is
highly conserved and ubiquitously expressed in human tissue [74].
PP2A is formed of three subunits, all of which have at least two iso-
forms [75]. Subunit A contains one of two isoforms, α encoded by
PPP2R1A and β encoded by PPP2R1B and forms the structural subunit,
which stabilises the whole complex. PP2A maintains cellular home-
ostasis by negatively regulating signalling pathways that have been
initiated by protein-kinases. Specifically, PP2A is required for chro-
mosome segregation through its interactions with Bub1 and Sgo1 [76].
PPP2R1Amutations are heterozygous and cluster at particular hotspots:
p. R183W, p. R183 G and p. R182W, suggesting that it may function as
an oncogene. The two arginine residues that are mutated in OCCC are
highly conserved and reside within one of the Huntington, elongation
factor 3, PP2A, TOR (HEAT) domains of PPP2R1A that are involved in
binding regulatory subunits [41]. Mutations affecting both isoforms of
PP2A subunit A, have been identified in a variety of tumours: PPP2R1A
(breast, lung, melanoma) and PPP2R1B (breast), albeit at a low
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frequency [77]. Although PPP2R1A displays the mutation profile that
would impart oncogenic function, its role is not established in OCCC.
However, in uterine cancers PPP2R1A hotspot mutations have been
shown to trigger hyperphosphorylation of oncogenic PP2A-B56/B'
substrates in the GSK3β, AKT, and mTOR/p70S6K signalling pathways,
suggesting that PI3K pathway inhibition may be a useful therapeutic
strategy, however this hasn’t been formally tested to date [78]. Inter-
estingly in haematological malignancies, such as chronic myeloid leu-
kaemia, PPP2R1A is postulated to be a tumour suppressor, with re-
storation of functional PP2A possible with PP2A activating drugs such
as forskolin [79].
8. Targeting the PI3K pathway
Activation of the phosphatidylinositol 3-kinase (PI3K)/AKT/ mam-
malian target of rapamycin (mTOR) pathway is known to play an im-
portant role in the pathogenesis of OCCC, and is involved in a number
of cellular functions required for cancer cells to sustain proliferation,
cell adhesion and apoptosis, and regulates G1 cell cycle progression in
ovarian cancer cells [80]. Overall as the PI3K/AKT/mTOR signalling
pathway is more frequently activated in OCCCs [81], it would suggest
that therapeutic inhibition of the pathway would be a viable targeted
approach to treatment. Although a significant enrichment of co-existing
PIK3CA and PTEN mutations have been associated with ARID1A mu-
tations in OCCC (Table 1), suggesting there may be a synthetic-lethal
relationship between PI3K pathway activation and ARID1A loss, this
has not been substantiated in patient derived models [82]. However, it
is clear from the use of orthotopic genetically engineered mouse models
(GEMMs), that PIK3CA activation is needed concurrently with in-
activation of ARID1A to give rise to highly penetrant tumours with
OCCC histopathology [46]. In this GEMM model, the animals had a
base-line median survival of around 7.5 weeks and treatment with
BKM120, a pan-PI3K inhibitor led to improved survival of 11 weeks,
demonstrating efficacy with this targeted approach [46]. In the context
of clinical trials in human OCCC patients, the GOG268 Japanese phase
II study assessing first-line carboplatin and paclitaxel with the addition
the mTOR inhibitor temsirolimus in patients with Stage III-IV OCCC,
was a well-tolerated regimen with 54% of optimally debulked patients
having a PFS greater than 12 months, however, this was not statistically
significant compared to historical controls. A recently published case
report described a 36-year-old relapsed OCCC patient, who had 3 al-
terations in PTEN and PIK3CA who derived 27 months of benefit from
everolimus, in the 4th line setting after genomic profiling of her liver
metastatectomy [50]. A Japanese study had one relapsed OCCC patient
out of 6 treated with temsirolimus who managed a partial response for
14 months [83]. There are now a number of trials in ovarian cancer (not
OCCC specific) looking at AKT inhibitors (single agent AZD5364,
NCT01226316; MK2206, NCT01283035), PI3K inhibitor and MEK in-
hibitor combinations (BKM120 and MEK162, NCT01363232), PI3K
inhibitor and PARP inhibitor (BKM120 or BYL719 and Olaparib,
NCT01623349) and a PI3K/HDAC inhibitor (CUDC-907,
NCT02307240). However, these studies and trails have not correlated
findings to ARID1A status to date.
9. ARID1A alterations as patient selection biomarkers for clinical
trials
Given the high frequency of ARID1A defects in multiple tumour
types that may be eligible for treatment, translation of the synthetic-
lethal findings into clinical trials highlights that ARID1A assessment for
patient stratification is an area of unmet need. One obvious way to do
this, is through targeted sequencing approaches, however ARID1A
mutational analysis alone is not straightforward as there are no “hot-
spot mutations” and the entire gene will need to be sequenced.
Furthermore, mutational analysis will not incorporate post-transla-
tional modifications that may impact on the functionality of ARID1A.
Therefore, a surrogate biomarker of mutational status such as IHC is
needed. Although IHC has been shown to be a useful tool in predicting
ARID1A mutational status in the research setting there is no uniform
scoring system or specific antibody that is recommended for clinical use
to date. Work from our lab has systematically assessed a number of
commercially available antibodies and identified EPR13501 as a robust
biomarker of ARID1A status with a cut-off of< 8 identifying mutated
cases, using our optimised scoring system [84]. This will be useful for
recruiting patients for clinical trials based on ARID1Amutational status.
The ENGOT-GYN1/NCRI/ATARI that utilises our findings is planned to
open in 2019 using this approach, allowing validation and evaluation of
the IHC scoring system in the context of a prospective clinical trial.
Currently there are no clinical trials recruiting patients that pro-
spectively assess ARID1A mutational status. However, there are a
number of early phase trials investigating ARID1A mutational status
and response to therapy, the first of which allocates treatment to pa-
tients with advanced solid tumours whose biopsies are sequenced as
part of ongoing clinical sequencing programmes outside of the remit of
the clinical trial [85]. Patients with PIK3CA, AKT or ARID1A mutations
will receive olaparib with the AKT inhibitor AZD5363. Table 3 high-
lights a number of current clinical OCCC trials including a randomised
phase II study of nintedanib compared to chemotherapy in patients
with clear cell carcinoma of the ovary or endometrium, which will
assess ARID1A mutational status retrospectively and correlate with
outcome [34] and a trial assessing dasatinib in patients with recurrent
or persistent ovarian, fallopian tube, endometrial or peritoneal carci-
noma which will retrospectively compare ARID1A mutational and IHC
status [86]. These trials highlight that prospectively assessing ARID1A
mutational status is potentially cost-prohibitive and the turnaround
time can make it difficult for trial recruitment. Upfront sequencing costs
are still expensive and time-consuming for the majority of academic
trials, whereas the costs and practicalities of IHC are more realistic, in
particular given the need for many of these patients to start therapy
soon due to the rapid nature of disease progression and limited life
expectancy.
10. Emerging role of the immune landscape in OCCC
The immune microenvironment is now considered to be of im-
portance in both tumour development and pathogenesis. The ability of
a tumour to evade immune destruction has led to it being described as
an emerging hallmark of cancer [87]. Immuno-oncology is a new ap-
proach to cancer treatment enabling the body’s immune system (T cells)
to detect and attack cancer cells with the potential to deliver long-term
responses, via the enhancement of T cell activation or reversal of tu-
mour-induced T cell inhibition. Several of these agents, such as anti-
bodies targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4) and pro-
grammed death receptor 1 (PD-1) have already demonstrated
significant promise in other tumour types in clinical trials [88].
Programme death 1 (PD-1) and programmed death ligand 1 (PD-L1)
monoclonal antibodies have been trialled in the recurrent ovarian
cancer setting with only modest response rates of up to 15%, although
no specific biomarkers have been identified [89]. Findings from various
cancer types highlight that mechanisms underlying the tumour immune
response are extremely complex and involve many different aspects of
the host immune system, tumour microenvironment, tumour genomics,
and cytokine/vascular milieu [90]. PD-L1 expression is associated with
poorer prognosis in ovarian cancer patients [91] and promotes perito-
neal dissemination of ovarian cancer [92]. Interestingly, a Phase II
study investigating best overall response using Nivolumab (an anti-PD-
1 antibody that blocks PD-1 signalling) in 20 platinum resistant ovarian
cancers had two patients with a durable complete response, of which
one was an OCCC patient who had a maintained complete response for
more than a year and ongoing at time of publication, although PD-L1
expression was not described [93].
Studies have shown that mismatch repair deficiency (MSI), caused
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by defects in the DNA of mis-match repair (MMR) genes, is in-
dependently predicative of response to PD-1 blockade. Pembrolizumab
has been approved as a single agent for cancers with microsatellite
instability regardless of tumour site of origin based on five clinical trials
as part of the KEYNOTE trial series (this is the first FDA tissue/site-
agnostic approval [94]). Indeed, MSI is seen in around 14% of OCCC’s
with strong correlation between alterations in the protein expression of
hMLH1 and hMSH2 [95]. Given that immunohistochemical testing is
routine in diagnostic laboratories this may be a practical upfront test
that may guide treatment and could change the landscape of access to
immuno-oncology drugs. Recent work has demonstrated that ARID1A
deficiency is related to a mis-match repair phenotype with ARID1A
mutant tumours showing an increase in CD8+TILS and activation of
the immune checkpoint via upregulation of Pdcd1 (which encodes for
PD-1) and sensitization to PD-L1 checkpoint blockade therapy in vivo
compared to ARID1A wild-type tumours in an ID-8 ARID1A deficient
ovarian orthotopic model. A proteomic screen identified an interaction
between MSH2 and ARID1A, with ARID1A recruiting MSH2 to chro-
matin during DNA replication, promoting MMR. In the ARID1A defi-
cient setting, MMR was compromised and a C > T mutation pattern
(seen commonly in MMR-deficient tumours [96]) and increased muta-
tional load was observed [97]. A phase II study (NCT01876511) eval-
uated the efficacy of pembrolizumab, a PD-1 inhibitor, in 86 patients
with advanced MMR-deficient cancers encompassing 12 tumour types.
Disease control was achieved in 77% of patients and complete re-
sponses were seen in 21% of patients. This is likely related to the large
number of mutation-associated neoantigens (MANAs) seen in MMR
deficient cancers, which predicts response of solid tumours to PD-1
blockade [98].
11. Discussion
There is a clear unmet clinical need for OCCC patients that show
poor responses to chemotherapy. There have been a number of ad-
vances in the understanding of the molecular background of OCCC in
the last decade, especially with ARID1A synthetic lethal approaches.
Being able to robustly identify patients who may benefit from targeted
therapy will be of the paramount importance. The use of robust bio-
markers such as ARID1A IHC will allow patients to be easily stream-
lined into appropriate trials. The upcoming ENGOT-GYN1/NCRI/
ATARI phase II trial (NCT04065269), looking at the ATR inhibitor,
AZD6738+/- olaparib in the recurrent OCCC setting, will use this ap-
proach to select patients with ARID1A deficiency upfront to direct
treatment. There is a role for smaller proof of concept phase II studies
specifically in OCCC due to the rarity of the disease, which will require
international collaboration in order to accrue patients and obtain re-
sults in a timely fashion. Changing how we approach clinical trials
means strategic designs including use of basket trials will help the field
move forward. These are a novel approach to clinical trial design based
on the hypothesis that the presence of a molecular marker (independent
of tumour histological subtype) is predictive of response to therapy
[99]. Therefore, patients will be enrolled based on a molecular diag-
nostic test rather than tumour type. A recent example of this type of
approach is testing of PD-1 status in patients with deficient mismatch
repair (dMMR)/microsatellite instability-high (MSI-H) tumours, based
on the above clinical trial, NCT01876511) which confirmed that dMMR
is predictive of response to PD-1 blockade in solid tumours and has led
to the approval of pembrolizumab for dMMR patients, irrespective of
histology [98]. The upcoming NRG-GY-014 trial, in the recurrent
ovarian cancer setting assessing the EZH2 inhibitor tazemetostat will be
eagerly awaited. There is also great interest in PARP inhibitors, an-
giogenic and immunotherapy approaches. Combination treatments are
likely to be required to circumvent the emergence of resistance and to
improve on response rates. In the context of OCCC immunotherapy
trials, retrospective assessment of the response with tumour mutational
burden, MSI and ARID1A status will be needed to evaluate which
patient populations are likely to benefit from these therapies.
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